Hamdan Medical Journal (previously the Journal of Medical Sciences)

Table of Contents  

Plasma Endothelin-1, Homocysteine, and Nitric Oxide Levels in a Multiethnic Hypertensive Cohort from the United Arab Emirates

Enyioma N. Obineche, Abdishakur M. Abdulle, Javid Y. Pathan, Nico J. D. Nagelkerke
Published in : Journal of Medical Sciences ; Vol 3, No 3 (2010)
DOI : 10.2174/1996327001003030153

Abstract


Background: Hypertension is a major cause of morbidity and mortality in the United Arab Emirates (UAE). However, little is known regarding vasoactive biomarkers and lipid profiles in hypertensives versus normotensives in this heterogeneous ethnic population.

Aims: This study aimed to evaluate plasma endothelin-1 (ET-1), homocysteine (Hcy), nitric oxide (NO), and lipid parameters among hypertensive subjects and normotensives controls in a heterogeneous ethnic population from the UAE.

Methods: We collected venous samples from 164 hypertensive and 112 normotensive subjects matched for age, gender and ethnicity to determine their plasma levels of ET-1, Hcy and NO as well as their lipid profile.

Results: Hypertensive subjects displayed significantly higher plasma levels of ET-1 (p < 0.001) and NO (p < 0.001) but lower insulin levels (P<0.006) than normotensives. In contrast, there was no statistically significant difference with regard to Hcy concentrations. Very low-density lipoprotein (VLDL) and triglycerides (TG) levels were significantly (p < 0.01) higher in hypertensives than controls. Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and non-esterified fatty acids (NEFA) were significantly lower (p < 0.01) in hypertensives than normotensives.

Conclusion: In our heterogeneous ethnic population, levels of ET-1 and NO, but not of Hcy, were found to be associated with hypertension and may possibly contribute to an increased systemic vascular resistance among hypertensives. Whether the elevated ET-1 results are because of overproduction or decreased clearance remains to be ascertained Elevated levels of TG and VLDL, alongside with unaltered TC levels, seem to indicate the presence of type IV hypertriglyceridaemia.


Keywords


Hypertension; blood pressure; exercise; risk factor; special

View article in  :   PDF    

References


Grassi G. Role of the sympathetic nervous system in human hypertension. J Hypertens 1998; 16: 1979-87.

Treiber FA, Jackson RW, Davis H, Pollock JS, Kapuku G, Mensah GA, et al. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males. Hypertension 2000; 35: 722-5.

Nava E, Luscher TF. Endothelium-derived vasoactive factors in hypertension: Nitric oxide and endothelin. J Hypertens 1995; 13: S39-48.

Schiffrin EL. Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-43.

Massy ZA, Ceballos I, Chadefaux-Vekemens B, Nguyen-Khoa T, Descamps-Latscha B, Drueke TB, et al. Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. Kidney Int Suppl 2001; 78: S243- 5.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1986; 332: 411-5.

Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-70.

Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97: 752-6.

Jagla A, Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes 2001; 109: S533-47.

Ministry of Health Annual Report - United Arab Emirates - 1998; p. 28.

wald WT, Levy RI , Fredrickson DS. Estimation of the concentration of low-density lipoproteins in plasma, without the use of the preparative ultracentrifiige. Clin Chem 1972; 18: 499-502.

Obineche E, Abdulle AM, Bokhari AM, Yasin JY, Gillett MP. Circulating levels of endothelin-1 in a homogenous Gulf Arab population with untreated essential hypertension. Ann Saudi Med 2006; 26: 364-9.

Nava E, Luscher TF. Endothelium-derived vasoactive factors in hypertension: Nitric oxide and endothelin. J Hypertens 1995; 13: S39-48.

Schiffrin EL. Endothelin: Potential role in hypertension and vascular hypertrophy. Hypertension 1995; 25: 1135-43.

Ergul S, Ergul A, Hudson JA, Puett D, Wieman BM, Durham MD, et al. The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am J Hypertens 1998; 11: 1381-5.

Larouche I, Schiffrin EL. Cardiac microvasculature in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Hypertension 1999; 34: 795-801.

Yokokawa K, Tahara H, Kohno M, Murakawa K, Yasunari K, Nakagawa K, et al. Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 1991; 114: 213-5.

Herizi A, Jover B, Bouriquet N, Mimran A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension 1998; 31: 10-4.

Webb DJ, Strachan FE. Clinical experience with endothelial antagonists. Am J Hypertens 1998; 11: 71S-9S.

Quyyumi AA, Dakak N, Mulcahy D, Andrews NP, Husain S, Panza JA, et al. Nictric oxide activity in the atherosclerotic human coronary circulation. J Am Coll Cardiol 1997; 29: 308-17.

Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep 2007; 7: 191-9.

Jin L, Caldwell RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction viainhibition of arginine transport. J Physiol Pharmacol 2007; 58: 191-206.

Frank J, Beck SC, Flaccus A, Biesalski HK. No evidence for prooxidative effects of homocysteine in vascular endothelial cells. Eur J Nutr 2007; 46: 286- 292.





Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA